Trial Profile
Efficacy, Safety, and Tolerability of Fosmetpantotenate (RE-024), a Phosphopantothenate Replacement Therapy, in Pantothenate Kinase-Associated Neurodegeneration (PKAN) Patients: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fosmetpantotenate (Primary)
- Indications Pantothenate kinase-associated neurodegeneration
- Focus Adverse reactions; Therapeutic Use
- Acronyms FORT
- Sponsors Travere Therapeutics
- 02 Dec 2020 Status changed from active, no longer recruiting to discontinued.
- 16 Nov 2020 Results published in the Movement Disorders
- 14 Jun 2020 This trial has been discontinued in Poland (Global End Date: 2019-12-04), according to European Clinical Trials Database record.